Antineoplasic efect of hipoglucaemic drugs on experimental mammary tumors and malignant cell lines.

NÚÑEZ M; COCCA C; GUTIERREZ A; CROCI M; MARTIN G; CRICCO G; RIVERA; BERGOC R

Corfu, Grecia

Congreso; 7th International Conference of Anticancer Research; 2004

It is known that breast cell growth is dependent on several hormones and growth factors such as insulin and IGF-I. On the other hand, it has been reported that some hypoglycemic drugs including diarylsulphonylurea derivatives, have antitumoral activity.  The objective of this work was to evaluate the antitumoral action of glibenclamide (Gli), a second generation sulphonylurea in comparison with the antiestrogen Tamoxifen (Tam). In vivo studies were performed on an experimental model of mammary carcinoma induced in Sprague-Dawley rats by three ip inyections of N-Nitroso-N-Methylurea. Both Gli (0.2 mg/Kg/day po) and Tam (1mg/Kg/day ip), were administrated every day along 30 days when tumors reached a diameter of 6 mm. Neither Gli nor Tam modified glucose tolerance tests, plasmatic insulin and basal glucose levels. Besides, Gli treatment produced a regression of 64% of tumors, while treatment with Tam provoked a regression of 55% (P poster